Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Thyroid Eye Disease
Interventions: lonigutamab, Placebo; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Jacksonville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Benign Prostatic Hypertrophy
Interventions: Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 46
States / cities: Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more

Conditions: Healthy Volunteers
Interventions: iCP-NI, Placebo; Drug
Lead sponsor: Cellivery Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Asthma
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Creighton University; Other
Eligibility: 16 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more

Conditions: Moderate to Severe Nail Psoriasis
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more

Conditions: Schizophrenia
Interventions: Placebo, Paliperidone Palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 18
States / cities: Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Netherton Syndrome
Interventions: BCX17725, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: HIV Lipodystrophy
Interventions: Human recombinant leptin ("metreleptin"), Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Delay in Time to Lactogenesis Stage II
Interventions: Depo-Provera Injectable Product, Placebos; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Active Psoriatic Arthritis
Interventions: SUNPG1623 I, SUNPG1623 II, SUNPG1623 III, SUNPG1623 IV, PLACEBO; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Middleburg Heights, Ohio

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSV-F Vaccine, Phosphate Buffer Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more

Conditions: Osteoporosis
Interventions: Zoledronic acid, Placebo, Teriparatide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 89 Years · Female only
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more

Conditions: Pain, Postoperative
Interventions: VVZ-149 Injections, Placebo; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Dayton, Ohio + 2 more

Conditions: Urinary Tract Infections
Interventions: LBP-EC01, Placebo; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Anniston, Alabama • Irvine, California • Doral, Florida + 4 more

Conditions: Cocaine Use Disorder
Interventions: Semaglutide, Placebo, cognitive behavioral therapy (CBT).; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: HIV Infections
Interventions: PENNVAX®-GP HIV-1 DNA vaccine, Interleukin-12 (IL-12) DNA adjuvant, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Obesity
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 21
States / cities: Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more

Conditions: Knee Osteoarthritis, Cartilage Degeneration
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Christopher Ritchlin; Other
Eligibility: 40 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more

Search by objective public record fields.

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome

Postpartum Family Planning

Efficacy and Safety Study of SUNPG1623

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Teriparatide as a Chondroregenerative Therapy in OA

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1